Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Expands By 39.7%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 20,400 shares, an increase of 39.7% from the November 15th total of 14,600 shares. Based on an average daily trading volume, of 252,600 shares, the days-to-cover ratio is currently 0.1 days.

Chugai Pharmaceutical Stock Down 2.7 %

Chugai Pharmaceutical stock traded down $0.60 during midday trading on Friday, reaching $21.47. The stock had a trading volume of 84,614 shares, compared to its average volume of 127,388. The firm has a market capitalization of $70.64 billion, a PE ratio of 27.53 and a beta of 0.82. Chugai Pharmaceutical has a 12 month low of $14.52 and a 12 month high of $26.00. The firm's 50-day moving average price is $22.82 and its 200 day moving average price is $21.32.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.